1996
DOI: 10.1016/s0167-5273(96)02827-6
|View full text |Cite
|
Sign up to set email alerts
|

The nature of the cardiac myxoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
10
0
1

Year Published

2003
2003
2019
2019

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(14 citation statements)
references
References 21 publications
3
10
0
1
Order By: Relevance
“…Ki67 protein was not present in any cell type in the remaining 6 cases. In agreement with the previous report, 21 no p53-specific staining was seen here in any case of atrial myxoma. Expression of the p53 tumor gene is enhanced during development of many human tumors.…”
Section: Expression Of Calretinin Ki67 and P53 In Atrial Myxomasupporting
confidence: 94%
See 1 more Smart Citation
“…Ki67 protein was not present in any cell type in the remaining 6 cases. In agreement with the previous report, 21 no p53-specific staining was seen here in any case of atrial myxoma. Expression of the p53 tumor gene is enhanced during development of many human tumors.…”
Section: Expression Of Calretinin Ki67 and P53 In Atrial Myxomasupporting
confidence: 94%
“…Neither was detected in myxoma cells in the present study, denying a role of malignancy in the genesis of atrial myxoma. These data, combined with the presence of HSV-1 antigens and DNA, angiogenesis, and an inflammatory response, support the concept that atrial myxoma results from a benign, reactive process 21 and may be a chronic inflammatory lesion of endocardium. Mitosis and Ki67 expression are absent in multinucleate myxoma cells, suggesting that these cells may be formed by cell fusion rather than cell proliferation.…”
Section: Discussionsupporting
confidence: 67%
“… Abbreviations : ACTA2, actin, alpha2, smooth muscle [33,91]; ACTC1, actin, alpha, cardiac muscle1 [30]; C3, Compliment component 3 [27]; CCR2, chemokine receptor 2 [92]; CD34 and CD44(Indian blood group) [93,94]; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 5 [32,95]; CXCL1, chemokine ligand1 [25]; EDN1 and EDN3, endothelin1 and 3 [26]; ENG, endoglin [27]; FVIII/vWF, factor VIII related antigen/ von Willebrand factor [30,33]; FGF2, fibroblast growth factor2 [96]; FGFR1, fibroblast growth factor receptor1 [96]; FLT1/VEGFR1, fms-related tyrosine kinase 1 (vascular endothelial growth factor receptor) [30,97]; FMOD, fibromodulin [27]; FN1, fibronectin [27]; GATA4, GATA binding protein 4 [28]; HAND1, heart and neural crest derivatives expressed 1 [28]; IL6 and IL8, interleukin 6 & 8 [98]; ITGB4, integrin beta4 [27]; KRT19, keratin19 [63]; MCP1, Monocyte chemoattractant protein1 [92]; MIA, melanocyte inhibitory activity [27]; MIB1, mindbomb homolog1 [99]; MMP, matrix metallopeptidase [100]; MUC5AC, mucin5AC [101]; MYH10, myosin, heavy chain10 [102]; NFATC1, nuclear factor of activated T cells [30]; NKX2-5, transcription factor related locus 5 [28]; NOTCH1, Notch homolog1 [30]; PCNA, proliferating cell nuclear antigen [96,103]; PDGF-AA, alpha platelet derived growth factor alpha [97]; PECAM1, platelet endothelial cell adhesion molecule [33,103]; PKP2, plakophilin 2 [104]; PLA2G2A: phospholipaseA2 [26]; RB1, retinoblastoma1 [105]; SMAD6, family member 6 [30]; SOX9, (sex determining region)-box9 [27,30]; SPP1, secreted phosphoprotein1 [27]; TNC, tenascin C [94]; TIMP2...…”
Section: Figurementioning
confidence: 99%
“…Kodama et al detected cardiomyogenic specific expression of transcription factors in myxoma arguing for a neoplasm arising from mesenchymal cells [3]. However, heterologous components such as cartilage are recurrently reported in myxoma and argue for a reactive change/thrombosis or hamartoma [4]. In this case as a further explanation it has to be discussed that a small primary myxoma was added by secondary finally leading to the large atrial mass.…”
mentioning
confidence: 80%